The 10 references without contexts in paper V. Dobronravov A., A. Smirnov V., A. Bezrukikh M., N. Bystrova N., Yu. Drozdova V., S. Orlova A., В. Добронравов А., А. Смирнов В., А. Безруких М., Н. Быстрова Н., Ю. Дроздова В., С. Орлова А. (2006) “АНЕМИЯ И ПРЕДДИАЛИЗНЫЕ СТАДИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ, РАСПРОСТРАНЕННОСТЬ И ФАКТОРЫ РИСКА // ANEMIA AND PRE-DIALYSIS STAGES OF CHRONIC KIDNEY DISEASE: CLINICAL SIGNIFICANCE, INCIDENCE AND RISK FACTORS” / spz:neicon:nefr:y:2006:i:3:p:7-13

45
Jungers PY, Choukroun G, Oualim Z et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16(2): 307-312
(check this in PDF content)
46
Becker BN, Becker YT, Leverson GE, Heisey DM: Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17(9): 1667-1673
(check this in PDF content)
47
Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77(2):176-185
(check this in PDF content)
48
The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18(1):50-59
(check this in PDF content)
49
Krmar RT, Gretz N, Klare B et al. Renal function in predialysis children with chronic renal failure treated with erythropoietin. Pediatr Nephrol 1997;11(1):69-73
(check this in PDF content)
50
Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60(4):390-396
(check this in PDF content)
51
Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321(3):158-163
(check this in PDF content)
52
Smith RD, Schulman G et al.Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24(5):777-784
(check this in PDF content)
53
Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double­ blind placebo-controlled trial. Ann Intern Med 1989; 110(2): 108-114 55. Abraham PA, Opsahl JA, Rachael KM et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990;10(2):128-136 56. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000;75: S22-S26 57. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6): 2351-2366 58. Mazzali M, Jefferson JA, Vaziri ND, J
(check this in PDF content)
54
877-884 64. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339­ 1344 65. Ross R, McCrea J, Besarab A. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved.
(check this in PDF content)